Johnson & Johnson (JNJ) MedTech Chairman Tim Schmid noted the planned separation of the company's orthopedics business, expected around mid-2027, with various separation structures being evaluated. He also reported "resoundingly positive" feedback for the newly FDA-approved OTTAVA surgical robot system, with pilot launch sites being selected and more details expected at the December 8 Investor Day.